Merdury Biopharmaceutical Corporation (TPEX:6932)
Taiwan
· Delayed Price · Currency is TWD 7.99
-0.30 (-3.62%)
At close: Mar 9, 2026
Merdury Biopharmaceutical Company Description
Merdury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan.
The company develops StackDose platform, a drug development technology platform that integrates drug formulation, 3D powder printing, and hardware and software technologies to create drug-specific 3D printing production equipment, which can be used as a foundation for pharmaceutical companies to provide hosted services and in-house product development.
Merdury Biopharmaceutical Corporation was founded in 2019 and is headquartered in New Taipei City, Taiwan.
Merdury Biopharmaceutical Corporation
| Country | Taiwan |
| Founded | 2019 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| CEO | Yaoren Liang |
Contact Details
Address: No. 653, Bannan Rd. New Taipei City, 235030 Taiwan | |
| Phone | 886 2 8221 2020 |
| Website | merdury.com |
Stock Details
| Ticker Symbol | 6932 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006932007 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Yaoren Liang | GM and Director |
| Chun Chun Zhang | Vice President of Administration and Accounting Supervisor |
| Ruixing Chen | Legal Director and Director |
| Nanxiong Zhang | Chief Marketing Officer and Director |
| Chaoyi Chen | Chief Research and Development Officer |